10 of 11
SOLIMAN ET AL.
|
1
2
0.02, k = 11.28). H NMR (300 MHz, CDCl
3
); δ 7.32–7.21 (m, 4H),
[9] B. N. Halpern, Arch. Int. Pharmacodyn. Ther. 1942, 68, 339.
[
[
[
[
10] P. B. Marshall, Br. J. Pharmacol. 1955, 10, 270.
11] S. J. Hill, J. M. Young, Mol. Pharmacol. 1981, 19, 379.
12] M. E. Parsons, C. R. Ganellin, Br. J. Pharmacol 2009, 147, S127.
13] J. M. Cargill, J. H. B. Saunders, N. Peden, K. G. Wormsley, Lancet
1978, 312, 1113.
7
.18–7.11 (m, 1H), 5.55 (t, J = 5.7 Hz, 1H), 5.45 (t, J = 5.5 Hz, 1H), 3.39
(q, J = 6.2 Hz), 3.08–2.96 (m, 4H), 2.60 (s, 8H), 2.26 (t, J = 6.6 Hz, 2H),
1
3
1
.53–1.36 (m, 4H), and 1.30–1.19 (m, 4H).
); δ 159.70, 134.57, 129.66, 129.27, 126.76, 118.40, 58.94,
5.04, 41.93, 40.91, 33.21, 28.91, 27.97, 26.06, and 24.59. HRMS
C NMR (75 MHz,
CDCl
3
[
14] J. W. Freston, Gastroenterology 1978, 74, 426.
5
+
+
[15] E. Schlicker, M. Kathmann, in Pharmacochemistry Library, Elsevier,
Amsterdam 1998, pp. 13–26.
(
ESI–MS): m/z [M+H ] calculated for C19
30 5 2
H N S : 392.1944, found
3
29 5 2
92.1942; C19H N S (391.60).
[
16] K. Sander, T. Kottke, H. Stark, Biol. Pharm. Bull. 2008, 31, 2163.
17] C. Ferrada, S. Ferré, V. Casadó, A. Cortés, Z. Justinova, C. Barnes, E.
I. Canela, S. R. Goldberg, R. Leurs, C. Lluis, R. Franco, Neuropharma-
cology 2008, 55, 190.
[
4
.2
|
Pharmacology
4
.2.1 | Materials
[18] F. H. Darras, S. Pockes, G. Huang, S. Wehle, A. Strasser, H.‐J.
Wittmann, M. Nimczick, C. A. Sotriffer, M. Decker, ACS Chem.
Neurosci. 2014, 5, 225.
Histamine dihydrochloride was purchased from Alfa Aesar GmbH &
3
Co. KG (Karlsruhe, Germany). [ H]Mepyramine (specific activity:
[19] B. Sadek, A. Saad, A. Sadeq, F. Jalal, H. Stark, Behav. Brain Res. 2016,
312, 415.
3
α
2
0.0 Ci/mmol), [ H]N ‐methylhistamine (specific activity: 85.3 Ci/
[
[
[
20] B. Sadek, N. Khan, F. H. Darras, S. Pockes, M. Decker, Physiol. Behav.
3
mmol), and [ H]histamine (specific activity: 25.0 Ci/mmol) were
2
016, 165, 383.
3
acquired from Hartmann analytic (Braunschweig, Germany). [ H]‐
21] M. Rapanelli, L. Frick, V. Pogorelov, H. Ohtsu, H. Bito, C. Pittenger,
Transl. Psychiatr. 2017, 7, e1013.
[63]
UR‐DE257 was synthesized in our laboratories.
were dissolved in Millipore water + 1 eq. of HCl.
All stock solutions
22] M. Rodríguez‐Ruiz, E. Moreno, D. Moreno‐Delgado, G. Navarro, J.
Mallol, A. Cortés, C. Lluís, E. I. Canela, V. Casadó, P. J. McCormick, R.
Franco, Mol. Neurobiol. 2017, 54, 4537.
[
[
[
23] C. Robin Ganellin, J.‐C. Schwartz, H. Stark, Success. Drug Discov.
4
.2.2 | Methods
2
018, 3, 359.
24] K. Takeshita, K. Sakai, K. B. Bacon, F. Gantner, J. Pharmacol. Exp. Ther.
003, 307, 1072.
The pharmacological methods, which were used in this study
2
(
membrane preparation of Sf9 cells, radioligand‐binding assay)
25] R. L. Thurmond, P. J. Desai, P. J. Dunford, W.‐P. Fung‐Leung, C. L.
Hofstra, W. Jiang, S. Nguyen, J. P. Riley, S. Sun, K. N. Williams, J. P.
Edwards, L. Karlsson, J. Pharmacol. Exp. Ther. 2004, 309, 404.
26] G. Coruzzi, M. Adami, E. Guaita, I. J. P. de Esch, R. Leurs, Eur. J.
Pharmacol. 2007, 563, 240.
[33]
are already described in the literature.
[
ACKNOWLEDGMENTS
[
27] R. A. Smits, H. D. Lim, A. Hanzer, O. P. Zuiderveld, E. Guaita, M. Adami,
The authors thank Prof. Dr. Sigurd Elz for providing infrastructure
and scientific expertise. Steffen Pockes thanks Simon Duschl (B. Eng.)
for his support with image editing.
G. Coruzzi, R. Leurs, I. J. P. de Esch, J. Med. Chem. 2008, 51, 2457.
[28] P. J. Dunford, N. O’Donnell, J. P. Riley, K. N. Williams, L. Karlsson, R.
L. Thurmond, J. Immunol. 2006, 176, 7062.
[
29] M. E. Parsons, R. C. Blakemore, G. J. Durant, C. R. Ganellin, A. C.
Rasmussen, Inflamm. Res. 1975, 5, 464.
[
30] G. J. Durant, W. A. M. Duncan, C. R. Ganellin, M. E. Parsons, R. C.
Blakemore, A. C. Rasmussen, Nature 1978, 276, 403.
CONFLICT OF INTERESTS
The authors declare that there are no conflicts of interests.
[31] G. J. Durant, C. R. Ganellin, D. W. Hills, P. D. Miles, M. E. Parsons, E.
S. Pepper, G. R. White, J. Med. Chem. 1985, 28, 1414.
[
32] A. Buschauer, J. Med. Chem. 1989, 32, 1963.
[33] S. Pockes, D. Wifling, M. Keller, A. Buschauer, S. Elz, ACS Omega
018, 3, 2865.
[34] S. Pockes, D. Wifling, A. Buschauer, S. Elz, ChemistryOpen 2019, 8,
85.
35] P. Ghorai, A. Kraus, M. Keller, C. Go
ORCID
2
Steffen Pockes
2
[
̈
tte, P. Igel, E. Schneider, D.
Schnell, G. Bernhardt, S. Dove, M. Zabel, S. Elz, R. Seifert, A.
Buschauer, J. Med. Chem. 2008, 51, 7193.
REFERENCES
[
36] A. Kraus, P. Ghorai, T. Birnkammer, D. Schnell, S. Elz, R. Seifert,
S. Dove, G. Bernhardt, A. Buschauer, ChemMedChem 2009,
[
[
[
1] M. C. Lagerström, H. B. Schiöth, Nat. Rev. Drug Discov. 2008, 7, 339.
4
, 232.
2] A. S. F. Ash, H. O. Schild, Br. J. Pharmacol. Chemother. 1966, 27, 427.
3] J. W. Black, W. A. M. Duncan, C. J. Durant, C. R. Ganellin, E. M.
Parsons, Nature 1972, 236, 385.
[37] P. Ghorai, A. Kraus, T. Birnkammer, R. Geyer, G. Bernhardt, S. Dove,
R. Seifert, S. Elz, A. Buschauer, Bioorg. Med. Chem. Lett. 2010, 20,
3173.
[
4] J.‐M. Arrang, M. Garbarg, J.‐C. Schwartz, Nature 1983, 302, 832.
5] T. Oda, N. Morikawa, Y. Saito, Y. Masuho, S. Matsumoto, J. Biol.
Chem. 2000, 275, 36781.
[
38] T. Birnkammer, A. Spickenreither, I. Brunskole, M. Lopuch, N.
Kagermeier, G. Bernhardt, S. Dove, R. Seifert, S. Elz, A. Buschauer,
J. Med. Chem. 2012, 55, 1147.
[
[6] S. J. Hill, C. R. Ganellin, H. Timmerman, J. C. Schwartz, N. P. Shankley,
J. M. Young, W. Schunack, R. Levi, H. L. Haas, Pharmacol. Rev. 1997,
[39] N. Kagermeier, K. Werner, M. Keller, P. Baumeister, G. Bernhardt, R.
Seifert, A. Buschauer, Sel. GCPR Ligands 2015, 23, 3957.
[40] P. Igel, R. Geyer, A. Strasser, S. Dove, R. Seifert, A. Buschauer, J. Med.
Chem. 2009, 52, 6297.
49, 253.
[
7] L. B. Hough, Mol. Pharmacol. 2001, 59, 415.
[
8] A. M. Staub, D. Bovet, Compt. Rend. Soc. Biol. 1937, 125, 818.